AU2001289132A1 - Modified arginine deiminase - Google Patents

Modified arginine deiminase

Info

Publication number: AU2001289132A1
Authority: AU; Australia
Prior art keywords: group; compound; arginine deiminase; microorganism; adi
Prior art date: 2000-11-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001289132A

Other languages

English (en)

Inventor

Mike A. Clark

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Phoenix Pharmacologics Inc

Original Assignee

Phoenix Pharmacologics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-28

Filing date

2001-09-19

Publication date

2002-06-11

2000-11-28 Priority claimed from US09/723,546 external-priority patent/US6737259B1/en

2001-09-19 Application filed by Phoenix Pharmacologics Inc filed Critical Phoenix Pharmacologics Inc

2002-06-11 Publication of AU2001289132A1 publication Critical patent/AU2001289132A1/en

Status Abandoned legal-status Critical Current

Links

108010082340 Arginine deiminase Proteins 0.000 title claims description 129
125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 title 1
229920001223 polyethylene glycol Polymers 0.000 claims description 95
239000002202 Polyethylene glycol Substances 0.000 claims description 85
206010028980 Neoplasm Diseases 0.000 claims description 37
125000005647 linker group Chemical group 0.000 claims description 36
150000001875 compounds Chemical class 0.000 claims description 33
238000000034 method Methods 0.000 claims description 30
201000001441 melanoma Diseases 0.000 claims description 26
241000204031 Mycoplasma Species 0.000 claims description 21
244000005700 microbiome Species 0.000 claims description 21
206010073071 hepatocellular carcinoma Diseases 0.000 claims description 19
AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 claims description 13
241000204028 Mycoplasma arginini Species 0.000 claims description 13
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 12
206010027476 Metastases Diseases 0.000 claims description 10
KQTSOJHOCCWAEH-UHFFFAOYSA-N n'-(2,5-dioxopyrrolidin-1-yl)butanediamide Chemical compound NC(=O)CCC(=O)NN1C(=O)CCC1=O KQTSOJHOCCWAEH-UHFFFAOYSA-N 0.000 claims description 10
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 9
-1 succinimidyl Chemical group 0.000 claims description 8
206010003246 arthritis Diseases 0.000 claims description 7
QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 claims description 6
206010039491 Sarcoma Diseases 0.000 claims description 6
125000004185 ester group Chemical group 0.000 claims description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
241000194108 Bacillus licheniformis Species 0.000 claims description 4
241001148604 Borreliella afzelii Species 0.000 claims description 4
241000589969 Borreliella burgdorferi Species 0.000 claims description 4
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 4
241000193468 Clostridium perfringens Species 0.000 claims description 4
241000186612 Lactobacillus sakei Species 0.000 claims description 4
125000003368 amide group Chemical group 0.000 claims description 4
150000001720 carbohydrates Chemical class 0.000 claims description 4
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
125000003700 epoxy group Chemical group 0.000 claims description 4
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 4
125000005462 imide group Chemical group 0.000 claims description 4
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
241000194033 Enterococcus Species 0.000 claims description 3
241000194032 Enterococcus faecalis Species 0.000 claims description 3
229940032049 enterococcus faecalis Drugs 0.000 claims description 3
241000193830 Bacillus <bacterium> Species 0.000 claims description 2
241000589968 Borrelia Species 0.000 claims description 2
241000193403 Clostridium Species 0.000 claims description 2
241000186660 Lactobacillus Species 0.000 claims description 2
208000016604 Lyme disease Diseases 0.000 claims description 2
241000202934 Mycoplasma pneumoniae Species 0.000 claims description 2
229940039696 lactobacillus Drugs 0.000 claims description 2
230000002708 enhancing effect Effects 0.000 claims 2
230000002476 tumorcidal effect Effects 0.000 claims 1
239000004475 Arginine Substances 0.000 description 32
235000009697 arginine Nutrition 0.000 description 32
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 32
150000001413 amino acids Chemical group 0.000 description 30
210000002966 serum Anatomy 0.000 description 29
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 24
241000699670 Mus sp. Species 0.000 description 23
229960002173 citrulline Drugs 0.000 description 23
230000000694 effects Effects 0.000 description 23
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 22
235000013477 citrulline Nutrition 0.000 description 22
210000004027 cell Anatomy 0.000 description 18
241001465754 Metazoa Species 0.000 description 15
235000018102 proteins Nutrition 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 15
102000004190 Enzymes Human genes 0.000 description 14
108090000790 Enzymes Proteins 0.000 description 14
229940088598 enzyme Drugs 0.000 description 14
239000000203 mixture Substances 0.000 description 14
201000011510 cancer Diseases 0.000 description 13
238000001727 in vivo Methods 0.000 description 11
238000011282 treatment Methods 0.000 description 11
238000002474 experimental method Methods 0.000 description 8
239000000872 buffer Substances 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
230000012010 growth Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
241000699660 Mus musculus Species 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000007423 decrease Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000012986 modification Methods 0.000 description 5
238000011580 nude mouse model Methods 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 4
102000053640 Argininosuccinate synthases Human genes 0.000 description 4
108700024106 Argininosuccinate synthases Proteins 0.000 description 4
108010024976 Asparaginase Proteins 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
230000001093 anti-cancer Effects 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
235000020776 essential amino acid Nutrition 0.000 description 4
239000003797 essential amino acid Substances 0.000 description 4
230000009401 metastasis Effects 0.000 description 4
230000004048 modification Effects 0.000 description 4
150000003141 primary amines Chemical class 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
241000282412 Homo Species 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
108090000371 Esterases Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
229960003272 asparaginase Drugs 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
DSEORJACOQDMQX-UHFFFAOYSA-N bis(2,3,4-trichlorophenyl) carbonate Chemical compound ClC1=C(Cl)C(Cl)=CC=C1OC(=O)OC1=CC=C(Cl)C(Cl)=C1Cl DSEORJACOQDMQX-UHFFFAOYSA-N 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
230000000593 degrading effect Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
235000018977 lysine Nutrition 0.000 description 2
125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
OKXGHXHZNCJMSV-UHFFFAOYSA-N nitro phenyl carbonate Chemical compound [O-][N+](=O)OC(=O)OC1=CC=CC=C1 OKXGHXHZNCJMSV-UHFFFAOYSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000000746 purification Methods 0.000 description 2
241000894007 species Species 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
101710191958 Amino-acid acetyltransferase Proteins 0.000 description 1
102000009042 Argininosuccinate Lyase Human genes 0.000 description 1
KDZOASGQNOPSCU-WDSKDSINSA-N Argininosuccinic acid Chemical compound OC(=O)[C@@H](N)CCC\N=C(/N)N[C@H](C(O)=O)CC(O)=O KDZOASGQNOPSCU-WDSKDSINSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
101000784014 Homo sapiens Argininosuccinate synthase Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
206010024218 Lentigo maligna Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
206010029488 Nodular melanoma Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
239000012564 Q sepharose fast flow resin Substances 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108010092464 Urate Oxidase Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
206010000583 acral lentiginous melanoma Diseases 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
230000002009 allergenic effect Effects 0.000 description 1
208000006431 amelanotic melanoma Diseases 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
210000002255 anal canal Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
150000001483 arginine derivatives Chemical class 0.000 description 1
KDZOASGQNOPSCU-UHFFFAOYSA-N argininosuccinate Chemical compound OC(=O)C(N)CCCN=C(N)NC(C(O)=O)CC(O)=O KDZOASGQNOPSCU-UHFFFAOYSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
230000000266 injurious effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
208000011080 lentigo maligna melanoma Diseases 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
201000000032 nodular malignant melanoma Diseases 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002924 oxiranes Chemical group 0.000 description 1
239000008188 pellet Substances 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
208000011584 spitz nevus Diseases 0.000 description 1
208000030457 superficial spreading melanoma Diseases 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000402 unacceptable toxicity Toxicity 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03006—Arginine deiminase (3.5.3.6)
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

AU2001289132A 2000-11-28 2001-09-19 Modified arginine deiminase Abandoned AU2001289132A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/723,546 US6737259B1 (en)	1997-05-12	2000-11-28	Modified arginine deiminase
US09/723,546		2000-11-28
PCT/US2001/029184 WO2002044360A2 (fr)	2000-11-28	2001-09-19	Arginine deiminase modifiee

Publications (1)

Publication Number	Publication Date
AU2001289132A1 true AU2001289132A1 (en)	2002-06-11

Family

ID=24906720

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001289132A Abandoned AU2001289132A1 (en)	2000-11-28	2001-09-19	Modified arginine deiminase

Country Status (7)

Country	Link
EP (1)	EP1337630A2 (fr)
JP (1)	JP2004515232A (fr)
KR (1)	KR20040004449A (fr)
CN (1)	CN1518595A (fr)
AU (1)	AU2001289132A1 (fr)
CA (1)	CA2430077A1 (fr)
WO (1)	WO2002044360A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005538709A (ja) *	2002-06-20	2005-12-22	バイオ−キャンサー・トリートメント・インターナショナル・リミテッド	アルギニンを欠乏させることによってヒト悪性腫瘍を治療する医薬品及び方法
HK1053577A2 (en)	2002-06-20	2003-10-10	Bio-Cancer Treatment International Limited	Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
CN1809378B (zh)	2002-11-18	2010-06-23	德西涅Rx制药公司	体内抑制病毒复制的方法
WO2005107815A2 (fr) *	2004-05-03	2005-11-17	Nektar Therapeutics Al, Corporation	Dérivés de polymères comprenant un point de ramification de type imide
WO2006015512A1 (fr) *	2004-08-11	2006-02-16	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	Arginine déiminase modifiée
FR2884717B1 (fr) *	2005-04-25	2009-07-03	Erytech Pharma Soc Par Actions	Erythrocytes renfermant de l'arginine deiminase
CN101002945B (zh) *	2006-01-20	2012-09-05	清华大学	一种用于肿瘤治疗的新型复合物
CN100475270C (zh) *	2006-01-20	2009-04-08	清华大学	一种治疗肿瘤的药物及其应用
CN101812438B (zh) *	2010-03-25	2014-08-27	江苏泰康生物医药有限公司	一种精氨酸脱亚氨酶突变体及其制备与应用
CN102703339B (zh) *	2011-08-29	2013-08-14	山东恩贝生物工程有限公司	高产精氨酸脱亚胺酶菌株及用它生产l-瓜氨酸的方法
EP4582090A3 (fr)	2012-04-04	2025-09-17	Polaris Group	Composition comprenant de l'arginine déiminase pégylée
BR112015021483A2 (pt)	2013-03-15	2017-10-10	Polaris Group	arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
KR102523031B1 (ko) *	2014-03-18	2023-04-19	티디더블유 그룹	조작된 키메라성 페길화된 adi 및 사용 방법
ES2915382T3 (es)	2014-09-16	2022-06-22	Polaris Group	Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos ADI - PEG 20 para el tratamiento del cáncer
MX2019003475A (es) *	2016-09-29	2019-11-28	Meharry Medical College	Inhibidores bacterianos.
EP3534963B1 (fr)	2016-11-02	2024-04-17	Polaris Group	Formulations d'arginine déiminase pegylée
CN108265044B (zh) *	2016-12-31	2021-05-11	江苏众红生物工程创药研究院有限公司	聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN106591270B (zh) *	2017-01-23	2018-09-21	江南大学	一株定点突变改造的基因工程精氨酸脱亚胺酶
KR20250086810A (ko) *	2017-11-30	2025-06-13	재즈 파마슈티칼즈 아일랜드 리미티드	아스파라기나제를 이용한 치료 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3209338B2 (ja) *	1990-09-10	2001-09-17	株式会社ジャパンエナジー	ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5372942A (en) *	1992-02-10	1994-12-13	Coriell Institute For Medical Research	Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
US5804183A (en) *	1997-01-31	1998-09-08	Enzon, Inc.	Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6183738B1 (en) *	1997-05-12	2001-02-06	Phoenix Pharamacologics, Inc.	Modified arginine deiminase

2001
- 2001-09-19 AU AU2001289132A patent/AU2001289132A1/en not_active Abandoned
- 2001-09-19 JP JP2002546708A patent/JP2004515232A/ja active Pending
- 2001-09-19 EP EP01968928A patent/EP1337630A2/fr not_active Withdrawn
- 2001-09-19 KR KR10-2003-7007054A patent/KR20040004449A/ko not_active Ceased
- 2001-09-19 WO PCT/US2001/029184 patent/WO2002044360A2/fr not_active Ceased
- 2001-09-19 CA CA002430077A patent/CA2430077A1/fr not_active Abandoned
- 2001-09-19 CN CNA01819673XA patent/CN1518595A/zh active Pending

Also Published As

Publication number	Publication date
CN1518595A (zh)	2004-08-04
WO2002044360A2 (fr)	2002-06-06
EP1337630A2 (fr)	2003-08-27
KR20040004449A (ko)	2004-01-13
JP2004515232A (ja)	2004-05-27
WO2002044360A3 (fr)	2002-12-19
CA2430077A1 (fr)	2002-06-06

Publication	Publication Date	Title
US7323167B2 (en)	2008-01-29	Method of treatment with modified arginine deiminase
AU2001289132A1 (en)	2002-06-11	Modified arginine deiminase
Pasut et al.	2008	Anti-cancer PEG-enzymes: 30 years old, but still a current approach
JP5341945B2 (ja)	2013-11-13	非免疫原性ポリマー結合体の調製のための凝集体非含有尿酸オキシダーゼ
ES2296750T3 (es)	2008-05-01	Forma mutada de la arginina deiminasa.
WO2003082926A2 (fr)	2003-10-09	Conjugues de polymere antimicrobiens
CN101591649B (zh)	2013-02-13	甲氧基聚乙二醇修饰的精氨酸脱亚氨酶及其制备与应用
HK1144701B (en)	2014-06-06	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Legal Events

Date	Code	Title	Description
2007-05-10	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application